Hieff Trans™ Liposomal Transfection Reagent

Liposomal Transfection Reagent is a versatile liposome transfection reagent, suitable for DNA, RNA and oligonucleotide transfection, with high transfection efficiency for most eukaryotic cells. Its unique formula allows it to be added directly to the medium, and the presence of serum does not affect transfection efficiency, which reduces the damage to cells caused by serum removal.

For bulk purchasing, please click To Send an Inquiry

Details:

Product Description

Hieff TransTM Liposomal Transfection Reagent is a versatile liposome transfection reagent, suitable for DNA, RNA and oligonucleotide transfection, with high transfection efficiency for most eukaryotic cells. Its unique formula allows it to be added directly to the medium, and the presence of serum does not affect transfection efficiency, which reduces the damage to cells caused by serum removal. There is no need to remove the nucleic acid-Hieff TransTM complex or replace it with fresh medium after transfection, and it can also be removed after 4-6 hours.

Hieff TransTM is supplied in sterile liquid form. Usually, for 24-well plate transfection, about 1.5 μL each time, 1 mL of Hieff TransTM can do about 660 transfections; for 6-well plate, about 6 μL each time, 1 mL of Hieff TransTM can do about 660 transfections. 160 transfections.

Shipping and Storage

The product is shipped with ice packs and can be stored at 2-8ºC for one year. Do not freeze!

Cautions

1) Hieff TransTM Liposomal Transfection Reagent requires a high cell plating density, preferably 90%-95%, which helps to reduce the impact of cationic liposome cytotoxicity; if the gene you are studying requires a long time, for example, cell cycle-related genes or cell surface proteins, it is best to choose transfection reagents with lower cell plating density requirements, and liposomal nucleic acid transfection reagents are not suitable.

2) Hieff TransTM Liposomal Transfection Reagent can be used for transfection with serum medium, and it is not necessary to change the medium before and after transfection. However, the preparation of transfection complexes requires dilution of DNA and transfection reagents in a serum-free medium because serum can affect complex formation. In addition, to test the compatibility of the serum-free medium used with the liposomal nucleic acid transfection reagent, CD293, SFMII, VP-SFM are known to be incompatible.

3) Antibiotics should not be added to the medium during transfection.

4) The use of high-purity DNA or RNA helps to obtain higher transfection efficiency, and endotoxin in plasmids is the enemy of transfection.

5) Cationic liposomes should be stored at 4 degrees, and be careful not to open the lid repeatedly for a long time, because it may cause liposome oxidation and affect the transfection efficiency.

6) The DNA concentration and the amount of cationic liposome reagent should be optimized for maximum transfection efficiency for initial use. The ratio of DNA and transfection reagent is usually recommended to be 1:2-1:3, such as seeding 0.5-2×105 cells in a 24-well plate, using 0.5 µg DNA and 1-1.5 µL of transfection reagent. Optimize the transfection efficiency by adjusting the ratio of DNA/Hieff TransTM liposome nucleic acid transfection reagent to ensure that the cell density is greater than 90%, and the ratio of DNA (μg): Hieff TransTM (μL) is 1:0.5-1:5.

7) For research use only!

Instructions (Take the 24-well plate as an example, please refer to Table 1 for the loading volume of other culture plates) 

[Note]: The amount of transfection reagent used is affected by the cell type and other experimental conditions. It is recommended to set a gradient to optimize the optimal amount of use for the first time.

Adherent cells: One day before transfection (20-24 hours), trypsinize cells and count, and cells were plated (without antibiotics) to a density of 90-95% at the time of transfection (0.5-2 × 105 cells/well for a 24 -well plate).

Suspension cells: On the day of transfection, before preparing DNA complexes, plate cells in 24-well plates at 4-8 × 105 cells per 500 µL of growth medium (without antibiotics).

1. Prepare the DNA-Hieff TransTM Liposome Nucleic Acid Transfection Reagent Complex as follows:

1) For each well of cells, dilute 0.5 μg of DNA with 50 μL of serum-free medium (such as OPTI-MEM I medium). Mix well.

2) For each well of cells, dilute 0.6-2.5 μL of Hieff TransTM liposomal nucleic acid transfection reagent with 50 μL of serum-free medium (such as OPTI-MEM I medium).

Dilute Hieff TransTM Liposome Nucleic Acid Transfection Reagent and incubate at room temperature for 5 mins (mix with the diluted DNA within 30 mins, if the incubation time is too long, the activity will be reduced)

[Note]: If DMEM is used as a diluent for liposomal nucleic acid transfection reagent, it must be mixed with the diluted DNA within 5 mins. Even if the liposomal nucleic acid transfection reagent is diluted with OPTI-MEM I, cells can be cultured with DMEM.

2. Mix the diluted DNA and the diluted liposomal nucleic acid transfection reagent (total volume 100 µL), mix gently, and incubate at room temperature (15-25°C) for 20 mins to allow the formation of DNA-liposome complexes. The solution may be cloudy at this point, but it will not affect transfection.

[Note]: DNA-liposome complexes are stable at room temperature for at least 5 h.

3. Add 100 µL of DNA-Hieff TransTM complex directly to each well of the cell culture plate, shake the plate, and mix gently.

[Note]: If transfecting under serum-free conditions, use serum-containing normal growth medium for cell plating. Growth medium was removed before complex addition and replaced with 500 µL of serum-free medium.

4. Incubate at 37°C in a 5% CO2 incubator for 24-48 h until transgene expression analysis without removing complexes or changing medium. However, it may be necessary to change the growth medium after 4-6 h without reducing transfection activity.

Stably transfected cell line: 24 h after transfection, fresh growth medium was added to the cells at a ratio of 1:10 or higher, and selection medium was added 48 h after transfection.

Suspension cell line: After the DNA-Hieff TransTM complex was added to the cells, PMA and/or PHA could be added 4 h later if desired. For Jurkat cells, final concentrations of PHA and PMA were 1 µg/mL and 50 ng/mL, respectively, which increased CMV promoter activity and gene expression. For K562 cells, the addition of PMA alone was sufficient to increase promoter activity.

Adjustment of transfection system

For different cell culture plates, the amount of Hieff TransTM liposome nucleic acid transfection reagent, DNA, cells, and medium will be different, please refer to the following table (Table 1) for details. For 96-well plate culture, there is no need to plate cells one day in advance, and the complex can be prepared directly in the plate, and then the cell suspension can be added to the complex, which further reduces the transfection time. This modified procedure has been tested with 293-H, 293-F, COS-7L, and CHO cells and is slightly less active than the traditional method. Fast steps and efficient transfection of protein-expressing cell lines make liposomal nucleic acid transfection reagents ideal for high-throughput transfection in 96-well plates, such as cDNA library screening and transient protein expression.

Table 1 Amounts of liposomal nucleic acid transfection reagent, nucleic acid, cells, and medium for different culture vessels

Culture vessel

Surf. area per well 1

Shared reagents

DNA transfection

RNAi transfection

Vol. of plating medium

Vol. of dilution medium 2

DNA

transfection reagent

RNA

transfection reagent

96-well

0.3 cm2

100 μL

2×25 μL

0.1 μg

0.2-0.5 μL

5 pmol

0.25 μL

24-well

2 cm2

500 μL

2×50 μL

0.5 μg

0.6-2.5 μL

20 pmol

1.0 μL

12-well

4 cm2

1 mL

2×100 μL

1 μg

2-4.5 μL

40 pmol

2.0 μL

6-well

10 cm2

2 mL

2×250 μL

2-4 μg

5-10 μL

100 pmol

5 μL

60-mm

20 cm2

5 mL

2×0.5 mL

4-8 μg

10-20 μL

200 pmol

10 μL

10-cm

60 cm2

15 mL

2×1.5 mL

12-24 μg

30-60 μL

600 pmol

30 μL

1 The surface area of cell culture plates provided by different manufacturers may vary;

2 Volume of the medium used to dilute DNA or RNAi.

[Note]: The usage amount in this table is for reference only, and the specific usage amount needs to be optimized according to the cell type and other experimental conditions. DNA (μg):Hieff TransTM (μL) ratio was kept at 1:0.5-1:5 when use.

FAQs:

Hieff Trans™  Liposomal Transfection Reagent  FAQ

(1) Q: Can serum be present when preparing nucleic acid transfection reagent complex?

A: The presence of serum will affect the formation of liposomes. It is recommended to use serum-free medium (usually MEM medium) when preparing nucleic acid transfection reagent complexes.

(2) Q: Can the transfection reagent be frozen?

A: No. This reagent must be stored at 2-8 ℃, and care should be taken to avoid repeatedly opening the cap for a long time, as long-term opening of the cap will cause liposome oxidation and affect the transfection efficiency.

(3) Q: What should I pay attention to when using Hieff Trans™ Liposome Nucleic Acid Transfection Reagent?

A: 1) During the transfection operation, it is better that the cell confluence reaches 80%-95%, and the specific plating density is determined according to the situation of the cells;

2) Using high-purity DNA helps to obtain higher transfection efficiency;

3) DNA and transfection reagents are required to be diluted with serum-free medium when preparing transfection complexes;

4) Antibiotics cannot be added to the medium during transfection;

5) The DNA concentration and the amount of cationic liposome reagent should be optimized for the first use to obtain the maximum transfection efficiency. The ratio of DNA to transfection reagent is generally recommended to be 1:2-1:3.

(4) Q: Does it need to be terminated after transfection?

A: No need. Liposome complexes are stable for 6 hours. If the cell medium is not changed before transfection, in order to ensure the nutrients required for normal cell growth, it is necessary to change to a new medium after 4 to 6 hours. However, if the medium has been changed before transfection, it is not necessary to change the medium after liposome transfection.

(5) Q: What should I pay attention to if I want to improve the transfection efficiency?

A: a: The density of cells at the time of transfection is 90%-95%.

b: During transfection, use MEM serum-free medium for nucleic acid and liposome dilutions.

c: The medium can be changed 4-6h after transfection.

(6) Q: Can co-transfection of DNA and siRNA be performed? How's the effect?

A: Co-transfection can be performed, but it is recommended to perform separate transfection, and DNA transfection should be performed 6 hours after siRNA. If operated together, the siRNA transfection efficiency will be worse.

(7) Q: Can the transfection reagent be used for lentiviral packaging transfection?

A: Lentiviral packaging is possible, but the efficiency of lentiviral packaging is not necessarily related to the efficiency of transfection, but also related to the selection of packaging plasmids and the ratio between plasmids.

(8) Q: Can Hieff Trans™ Liposome Nucleic Acid Transfection Reagent be used for transfection of suspension cells?

 

A: Hieff Trans™ Liposome Nucleic Acid Transfection Reagent can be used for suspension cell transfection, see Protocol for details. In addition, we have also launched a transfection reagent specifically for suspension cells (Cat No. 40805, Liposome nucleic acid transfection reagent for suspension cells).

Citations & References:

[1] Liu R, Yang J, Yao J, Zhao Z, He W, Su N, Zhang Z, Zhang C, Zhang Z, Cai H, Zhu L, Zhao Y, Quan S, Chen X, Yang Y. Optogenetic control of RNA function and metabolism using engineered light-switchable RNA-binding proteins. Nat Biotechnol. 2022 Jan 3. doi: 10.1038/s41587-021-01112-1. Epub ahead of print. PMID: 34980910. (IF:54.908)

[2] Zhou J, Chen P, Wang H, Liu H, Li Y, Zhang Y, Wu Y, Paek C, Sun Z, Lei J, Yin L. Cas12a variants designed for lower genome-wide off-target effect through stringent PAM recognition. Mol Ther. 2022 Jan 5;30(1):244-255. doi: 10.1016/j.ymthe.2021.10.010. Epub 2021 Oct 20. PMID: 34687846; PMCID: PMC8753454. (IF:11.454)

[3] Chen S, Cao X, Zhang J, Wu W, Zhang B, Zhao F. circVAMP3 Drives CAPRIN1 Phase Separation and Inhibits Hepatocellular Carcinoma by Suppressing c-Myc Translation. Adv Sci (Weinh). 2022 Mar;9(8):e2103817. doi: 10.1002/advs.202103817. Epub 2022 Jan 24. PMID: 35072355; PMCID: PMC8922094. (IF:16.808)

[4] Zhang Y, Yu X, Sun R, Min J, Tang X, Lin Z, Xie S, Li X, Lu S, Tian Z, Gu C, Teng L, Yang Y. Splicing factor arginine/serine-rich 8 promotes multiple myeloma malignancy and bone lesion through alternative splicing of CACYBP and exosome-based cellular communication. Clin Transl Med. 2022 Feb;12(2):e684. doi: 10.1002/ctm2.684. PMID: 35184390. (IF:11.492)

[5] Tang X, Deng Z, Ding P, Qiang W, Lu Y, Gao S, Hu Y, Yang Y, Du J, Gu C. A novel protein encoded by circHNRNPU promotes multiple myeloma progression by regulating the bone marrow microenvironment and alternative splicing. J Exp Clin Cancer Res. 2022 Mar 8;41(1):85. doi: 10.1186/s13046-022-02276-7. PMID: 35260179. (IF:11.161)

[6] Hua Z, Wei R, Guo M, Lin Z, Yu X, Li X, Gu C, Yang Y. YTHDF2 promotes multiple myeloma cell proliferation via STAT5A/MAP2K2/p-ERK axis. Oncogene. 2022 Mar;41(10):1482-1491. doi: 10.1038/s41388-022-02191-3. Epub 2022 Jan 24. PMID: 35075244. (IF:9.867)

[7] Liang Y, Lu Q, Li W, Zhang D, Zhang F, Zou Q, Chen L, Tong Y, Liu M, Wang S, Li W, Ren X, Xu P, Yang Z, Dong S, Zhang B, Huang Y, Li D, Wang H, Yu W. Reactivation of tumour suppressor in breast cancer by enhancer switching through NamiRNA network. Nucleic Acids Res. 2021 Sep 7;49(15):8556-8572. doi: 10.1093/nar/gkab626. PMID: 34329471; PMCID: PMC8421228.  (IF:16.9)

[8] Dai L, Dai Y, Han J, Huang Y, Wang L, Huang J, Zhou Z. Structural insight into BRCA1-BARD1 complex recruitment to damaged chromatin. Mol Cell. 2021 Jul 1;81(13):2765-2777.e6. doi: 10.1016/j.molcel.2021.05.010. Epub 2021 Jun 7. PMID: 34102105. (IF:17.97)

[9] Zhang K, Wang A, Zhong K, Qi S, Wei C, Shu X, Tu WY, Xu W, Xia C, Xiao Y, Chen A, Bai L, Zhang J, Luo B, Wang W, Shen C. UBQLN2-HSP70 axis reduces poly-Gly-Ala aggregates and alleviates behavioral defects in the C9ORF72 animal model. Neuron. 2021 Jun 16;109(12):1949-1962.e6. doi: 10.1016/j.neuron.2021.04.023. Epub 2021 May 14. PMID: 33991504. (IF:17.17)

[10] Liang Y, Lu Q, Li W, Zhang D, Zhang F, Zou Q, Chen L, Tong Y, Liu M, Wang S, Li W, Ren X, Xu P, Yang Z, Dong S, Zhang B, Huang Y, Li D, Wang H, Yu W. Reactivation of tumour suppressor in breast cancer by enhancer switching through NamiRNA network. Nucleic Acids Res. 2021 Sep 7;49(15):8556-8572. doi: 10.1093/nar/gkab626. PMID: 34329471; PMCID: PMC8421228. (IF:16.9)

[11] Li T, Chen X, Qian Y, Shao J, Li X, Liu S, Zhu L, Zhao Y, Ye H, Yang Y. A synthetic BRET-based optogenetic device for pulsatile transgene expression enabling glucose homeostasis in mice. Nat Commun. 2021 Jan 27;12(1):615. doi: 10.1038/s41467-021-20913-1. PMID: 33504786; PMCID: PMC7840992. (IF:14.92)

[12] Pan Y, He X, Li C, Li Y, Li W, Zhang H, Wang Y, Zhou G, Yang J, Li J, Qu J, Wang H, Gao Z, Shen Y, Li T, Hu H, Ma H. Neuronal activity recruits the CRTC1/CREB axis to drive transcription-dependent autophagy for maintaining late-phase LTD. Cell Rep. 2021 Jul 20;36(3):109398. doi: 10.1016/j.celrep.2021.109398. PMID: 34289350. (IF:9.42)

[13] Liu H, Xing R, Ou Z, Zhao J, Hong G, Zhao TJ, Han Y, Chen Y. G-protein-coupled receptor GPR17 inhibits glioma development by increasing polycomb repressive complex 1-mediated ROS production. Cell Death Dis. 2021 Jun 12;12(6):610. doi: 10.1038/s41419-021-03897-0. PMID: 34120140; PMCID: PMC8197764. (IF:8.463)

[14] Fan Y, Wang J, Jin W, Sun Y, Xu Y, Wang Y, Liang X, Su D. CircNR3C2 promotes HRD1-mediated tumor-suppressive effect via sponging miR-513a-3p in triple-negative breast cancer. Mol Cancer. 2021 Feb 2;20(1):25. doi: 10.1186/s12943-021-01321-x. PMID: 33530981; PMCID: PMC7851937. (IF:27.403)

[15] Gu C, Wang Y, Zhang L, Qiao L, Sun S, Shao M, Tang X, Ding P, Tang C, Cao Y, Zhou Y, Guo M, Wei R, Li N, Xiao Y, Duan J, Yang Y. AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma. J Exp Clin Cancer Res. 2022 Jan 6;41(1):11. doi: 10.1186/s13046-021-02220-1. PMID: 34991674; PMCID: PMC8734095. (IF:11.161)

[16] Luo Q, Wu X, Zhao P, Nan Y, Chang W, Zhu X, Su D, Liu Z. OTUD1 Activates Caspase-Independent and Caspase-Dependent Apoptosis by Promoting AIF Nuclear Translocation and MCL1 Degradation. Adv Sci (Weinh). 2021 Feb 8;8(8):2002874. doi: 10.1002/advs.202002874. PMID: 33898171; PMCID: PMC8061361. (IF:15.84)

[17] Luo Q, Wu X, Nan Y, Chang W, Zhao P, Zhang Y, Su D, Liu Z. TRIM32/USP11 Balances ARID1A Stability and the Oncogenic/Tumor-Suppressive Status of Squamous Cell Carcinoma. Cell Rep. 2020 Jan 7;30(1):98-111.e5. doi: 10.1016/j.celrep.2019.12.017. PMID: 31914402. (IF:9.42)

[18] Sun X, Peng X, Cao Y, Zhou Y, Sun Y. ADNP promotes neural differentiation by modulating Wnt/β-catenin signaling. Nat Commun. 2020 Jun 12;11(1):2984. doi: 10.1038/s41467-020-16799-0. PMID: 32533114; PMCID: PMC7293280. (IF:14.911)

[19] Yang X, Wang H, Xie E, Tang B, Mu Q, Song Z, Chen J, Wang F, Min J. Rewiring ERBB3 and ERK signaling confers resistance to FGFR1 inhibition in gastrointestinal cancer harbored an ERBB3-E928G mutation. Protein Cell. 2020 Dec;11(12):915-920. doi: 10.1007/s13238-020-00749-z. PMID: 32632529; PMCID: PMC7719122. (IF:14.872)

[20] Chen, T., Chen, Y., Chen, H. et al. Dual-enzyme-propelled unbounded DNA walking nanomachine for intracellular imaging of lowly expressed microRNA. Nano Res. 12, 1055–1060 (2019). https://doi.org/10.1007/s12274-019-2344-5 (IF:8.21)

[21] Zhang X, Qi Z, Yin H, Yang G. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy. Theranostics. 2019 Jan 30;9(4):1096-1114. doi: 10.7150/thno.29673. PMID: 30867818; PMCID: PMC6401400. (IF:8.12)

[22] Zou Y, Wang A, Shi M, Chen X, Liu R, Li T, Zhang C, Zhang Z, Zhu L, Ju Z, Loscalzo J, Yang Y, Zhao Y. Analysis of redox landscapes and dynamics in living cells and in vivo using genetically encoded fluorescent sensors. Nat Protoc. 2018 Oct;13(10):2362-2386. doi: 10.1038/s41596-018-0042-5. PMID: 30258175; PMCID: PMC6714056. (IF:13.49)

[23] Zhang K, Zhao X, Chen X, Wei Y, Du W, Wang Y, Liu L, Zhao W, Han Z, Kong D, Zhao Q, Guo Z, Han Z, Liu N, Ma F, Li Z. Enhanced Therapeutic Effects of Mesenchymal Stem Cell-Derived Exosomes with an Injectable Hydrogel for Hindlimb Ischemia Treatment. ACS Appl Mater Interfaces. 2018 Sep 12;10(36):30081-30091. doi: 10.1021/acsami.8b08449. Epub 2018 Aug 29. PMID: 30118197. (IF:8.09)

 

[24] Hao H, Hu S, Chen H, Bu D, Zhu L, Xu C, Chu F, Huo X, Tang Y, Sun X, Ding BS, Liu DP, Hu S, Wang M. Loss of Endothelial CXCR7 Impairs Vascular Homeostasis and Cardiac Remodeling After Myocardial Infarction: Implications for Cardiovascular Drug Discovery. Circulation. 2017 Mar 28;135(13):1253-1264. doi: 10.1161/CIRCULATIONAHA.116.023027. Epub 2017 Feb 2. PMID: 28154007. (IF:18.881)